Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
One of the ways tumors get around chemotherapy is ‘don’t eat me’ signals — membrane proteins that cloak cells, keeping phagocytic macrophages at bay In 2016, Irving Weissman’s lab at Stanford spun out Forty Seven, a biotech startup with a set of monoclonals against one of these don’t-eat-me signals, the eponymous CD47. Just four years later, Gilead snatched up Forty Seven to add anti-CD47 monoclonal antibodies to their anticancer armamentarium, but so far, their and others’ anti-CD47 monoclonals haven’t performed in the clinic. Now, Amira Barkal, a PhD graduate from Weissman’s lab, has pushed out another startup, Pheast Therapeutics, targeting a new don’t-eat-me pathway, CD24 and its partner, Siglec-10.